Figure 8.

Effects of ensartinib (15 and 25 µM) and the model CYP3A4 inhibitor ketoconazole (10 µM) on the antiproliferative activity of 1 µM docetaxel in HepG2-CYP3A4 (A) and HepG2-EV (B) cells. Cells were exposed to the tested drugs alone or in tandem for 48 h, after which their viability was assessed using the MTT test. (C) Sensitization effects were computed using the data from viability measurements. Statistical analysis was performed using one-way ANOVA followed by Dunnett’s post hoc test (* p < 0.05 compared to no inhibitor). The plotted values are means ± SD for three independent experiments.